1 enrolling by invitation. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Enrolling by invitation 1 |
Follow CTX001: new trials by email Literature Review of CTX001 trials Research Report on CTX001
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Long-term Follow-up Study in Participants Who Received CTX001 CTX001 - Beta-Thalassemia, Thalassemia | Phase 3 | Enrolling by invitation | Vertex Pharmaceuticals Incorporated | 160 | 2021-01-20 | 2026-08-11 |
Anemia, Sickle Cell (1) · Genetic Diseases, Inborn (1) · Hematologic Diseases (1) · Hemoglobinopathies (1) · Thalassemia (1) · beta-Thalassemia (1)
Vertex Pharmaceuticals Incorporated (1)
Belgium (1) · Canada (1) · Germany (1) · Italy (1) · United Kingdom (1) · United States (1)